
## Amber Yasmeen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5958513/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. NAR Cancer, 2022, 4, zcac013.	3.1	5
2	Carboplatin plus paclitaxel weekly doseâ€dense chemotherapy for highâ€grade ovarian cancer: A reâ€evaluation. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 453-458.	2.8	5
3	Multiple lines of chemotherapy for patients with highâ€grade ovarian cancer: Predictors for response and effect on survival. International Journal of Cancer, 2021, 148, 2304-2312.	5.1	4
4	Sentinel Lymph Node Sampling as an Alternative to Lymphadenectomy in Patients With Endometrial Cancer and Obesity. Journal of Obstetrics and Gynaecology Canada, 2021, 43, 1136-1144.e1.	0.7	8
5	High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study. Cancer Cell International, 2021, 21, 308.	4.1	13
6	Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer. Frontiers in Oncology, 2021, 11, 695404.	2.8	10
7	Copresence of High-Risk Human Papillomaviruses and Epstein–Barr Virus in Colorectal Cancer: A Tissue Microarray and Molecular Study from Lebanon. International Journal of Molecular Sciences, 2021, 22, 8118.	4.1	6
8	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria. Nature Communications, 2021, 12, 5404.	12.8	20
9	Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. Frontiers in Oncology, 2021, 11, 745981.	2.8	3
10	Biguanides in combination with olaparib limits tumorigenesis of drugâ€resistant ovarian cancer cells through inhibition of Snail. Cancer Medicine, 2020, 9, 1307-1320.	2.8	13
11	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	1.4	14
12	Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer. Journal of Obstetrics and Gynaecology Canada, 2020, 42, 1339-1345.	0.7	5
13	Water-Pipe Smoking Exposure Deregulates a Set of Genes Associated with Human Head and Neck Cancer Development and Prognosis. Toxics, 2020, 8, 73.	3.7	5
14	Co-presence of human papillomaviruses and Epstein–Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients. Cancer Cell International, 2020, 20, 361.	4.1	25
15	The added value of sentinel node mapping in endometrial cancer. Gynecologic Oncology, 2020, 158, 84-91.	1.4	21
16	CAâ€125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced highâ€grade ovarian cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 933-940.	2.8	19
17	The impact of wait times on oncological outcome in highâ€risk patients with endometrial cancer. Journal of Surgical Oncology, 2020, 122, 306-314.	1.7	3
18	Risk factors for lymph nodes involvement in obese women with endometrial carcinomas. Gynecologic Oncology, 2019, 155, 27-33.	1.4	13

Amber Yasmeen

#	Article	IF	CITATIONS
19	Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. Molecular Cancer Research, 2019, 17, 2422-2431.	3.4	3
20	Targeted sequencing of histologically defined serous endometrial cancer reflects prognosis and correlates with preoperative biopsy. Gynecologic Oncology Reports, 2019, 30, 100521.	0.6	0
21	Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer, 2019, 19, 44.	2.6	11
22	Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecologic Oncology, 2018, 148, 553-558.	1.4	15
23	<i>Elaeagnus angustifolia</i> Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation. Nutrition and Cancer, 2018, 70, 297-305.	2.0	16
24	Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. Gynecologic Oncology Reports, 2018, 24, 43-47.	0.6	6
25	Epstein–Barr virus and its association with Fascin expression in colorectal cancers in the Syrian population: A tissue microarray study. Human Vaccines and Immunotherapeutics, 2017, 13, 1573-1578.	3.3	16
26	Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 2017, 144, 474-479.	1.4	25
27	Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecologic Oncology, 2017, 147, 30-35.	1.4	11
28	Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer, 2017, 17, 638.	2.6	82
29	Co-prevalence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. Human Vaccines and Immunotherapeutics, 2016, 12, 1-4.	3.3	42
30	Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines. International Journal of Gynecological Cancer, 2016, 26, 1213-1221.	2.5	29
31	Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. BMC Cancer, 2015, 15, 817.	2.6	25
32	E-Cadherin/Catenin Complex Modulations in Human Oral Cancer. , 2015, , 169-187.		0
33	Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3123-3136.	4.1	29
34	High-Risk HPVs and Human Carcinomas in the Syrian Population. Frontiers in Oncology, 2014, 4, 68.	2.8	23
35	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic Oncology, 2014, 134, 607-614.	1.4	97
36	Src inhibitors are promising therapy molecules for human cervical carcinomas. Medical Hypotheses, 2011, 77, 812-814.	1.5	9

Amber Yasmeen

#	Article	lF	CITATIONS
37	Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecologic Oncology, 2011, 121, 492-498.	1.4	113
38	Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV. Journal of Oncology, 2010, 2010, 1-10.	1.3	36
39	Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer. Journal of Oncology, 2010, 2010, 1-11.	1.3	56
40	Teucrium polium plant extract inhibits cell invasion and motility of human prostate cancer cells via the restoration of the E-cadherin/catenin complex. Journal of Ethnopharmacology, 2010, 129, 410-415.	4.1	43
41	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecologic Oncology, 2009, 115, 193-198.	1.4	28
42	Real-time continuous dielectrophoretic separation of malignant cells. , 2008, , .		1
43	High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis. Current Pharmaceutical Design, 2008, 14, 2159-2172.	1.9	39
44	ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis. Cell Cycle, 2007, 6, 2939-2943.	2.6	21
45	E6/E7 of HPV Type 16 Promotes Cell Invasion and Metastasis of Human Breast Cancer Cells. Cell Cycle, 2007, 6, 2038-2042.	2.6	83
46	Critical role for D-type cyclins in cellular transformation induced by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB-2 cooperation. Cancer Science, 2007, 98, 973-977.	3.9	15
47	ErbB receptors and epithelial-cadherin–catenin complex in human carcinomas. Future Oncology, 2006, 2. 765-781.	2.4	34